Letter from the founders
In September 2025, we raised a beaker to our 30th anniversary, celebrating three decades of fit-for-purpose antibody discovery and toasting the people who made it possible – including you. After all, if you’re reading this, you’re either already part of our orbit here at Antibody Solutions or you’re an innovator we simply haven’t had the pleasure of meeting yet. Either way, you’ve helped propel the industry forward, giving biopharma companies of all shapes and sizes the keys to unlock the potential of therapeutic antibodies.
What’s the next 30 years look like in our line of work? Given the current pace of change – and the forces dramatically shaping how organizations bring new treatments to market -- it’d be difficult to accurately predict what’s even 30 months ahead.
But we can say this with certainty. “The Antibody Way,” the sum of the culture and values that have govern our daily work, will endure. They will be what we lean on in the good times and in the less-good times. They are what have guided us to consistent growth and, perhaps more important, pioneering science. And they remain our best employee recruiting tool; when prospective teammates get a preview of the “how” that directs our “why,” they’re eager to be a part of it.
Challenges and opportunities abound in the near future of antibody discovery. We look forward to embracing them all with you.
With great appreciation and anticipation,
John Kenney, PhD Judy Lynch-Kenney
President & Co-Founder CFO & Co-Founder
30 Years of Scientific Expertise
In April 2025, Antibody Solutions integrated single plasma B-cell discovery services into Cellestive, our discovery platform, which already included pathways for both activated and memory B-cells. This newly-combined trifecta of services would prove particularly attractive to clients pursuing especially difficult targets, enabling them to leverage new processes and technologies while gaining access broader, deeper data to inform their decision-making.
Cellestive Launch
Antibody Solutions launches Cellestive, a discovery platform that empowers researchers to explore multiple antibody discovery pathways with confidence. By combining scientific expertise with a consultative, process-driven approach, Cellestive marked a major step forward in how we guide clients from target to lead—helping them navigate complex challenges and uncover opportunities that might otherwise remain hidden.
Global Reach
In 2019, Antibody Solutions moved into its current 33,000 sq. ft. facility in Santa Clara, designed to support state-of-the-art antibody discovery and development. This move allowed us to expand our capabilities, streamline operations, and continue delivering high-quality science to clients locally and across the globe.
Partnerships Continue to Grow
As the company’s client base and service offerings continued to expand, Antibody Solutions outgrew its existing facility and relocated in 2011 to a larger office and lab space in Sunnyvale, California. At the same time, the firm began collaborating with human antibody transgenic animal providers: first with OMT (OmniAb®), and later with Trianni, Harbour Antibodies™, and Alloy Therapeutics. This enabled Antibody Solutions to leverage its deep knowledge of animal-based antibody generation with the advantages of fully human antibodies for therapeutics development. In 2018, Antibody Solutions updated all of its brand messaging including a new logo, designed for Antibody Solutions by Inveniv.
Continued Growth
With demand for its services steadily growing, Antibody Solutions moved its operations in 2004 to a new facility in Mountain View, California. This larger space allowed for the installation of a vivarium to manage immunizations onsite. In 2006, as industry innovators began to more seriously explore the use of antibodies in therapeutics, Antibody Solutions became the first company to offer high-throughput screening of antibodies to cell-surface antigens using a custom-built, automated flow cytometry platform. In 2018, Antibody Solutions updated its brand to include a new identity, designed for the company by Inveniv.
Development, Scalability, and Flexibility
The years 1999 to 2001 saw dynamic, strategic growth at Antibody Solutions on both the technical and operational fronts. The company was an early adapter of tissue culture bioreactor flasks – taking the place of mouse ascites, a major animal welfare concern – before they became industry standard. Additionally, the company gained flexibility and scalability in delivering their expanding list of services through the development of a custom enterprise resource database that is still in use today.
Early Antibody Innovations Become Industry Standards
From its humble beginnings in Palo Alto, Antibody Solutions has sought to innovate. The prospect of creating original, innovative antibodies that could be tailored to meet critical needs made for an exciting business opportunity. The company was borne, in large part, from a market study that uncovered a major lack in the antibody therapeutics field: there was, at the time, no industry leader providing high-quality, fit-for-purpose antibody discovery serivces. Antibody Solutions sought to fill that gap, developing a platform of services that would enable more organizations a seat at the antibody therapeutics table.
.png?width=160&height=50&name=ANTI%20History%20Page%20Date%20Card%20(1).png "ANTI History Page Date Card (1)")
